Philip Campbell

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé et al. · The Lancet · 2019 · 438 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 313 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Incidence of Catheter-Related Bloodstream Infection Among Patients With a Needleless, Mechanical Valve–Based Intravenous Connector in an Australian Hematology-Oncology Unit

Kathryn Field, Caroline McFarlane, Allen Cheng et al. · Infection Control and Hospital Epidemiology · 2007 · 75 citations · Full text

Medicine, Hematology, Infectious Diseases +16

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +17